Skip to main content

Overcoming Knowledge Gaps in Thyroid Cancer Management

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding management and novel treatment options for differentiated and anaplastic thyroid cancer. Thyroid cancer is one of the most prevalent cancers in the United States. The American Cancer Society estimates 43,720 new cases and 2,120 deaths from the disease in the United States over the course of 2023. Thyroid cancer is typically more aggressive in men than in women and becomes increas...

Continue reading

GLAONS Survey of Oncology Nurses Reveals Knowledge Gap Regarding Novel Treatment Options

In September 2022, i3 Health conducted a survey of 157 oncology nurses at the Greater Los Angeles Oncology Nursing Society (GLAONS) 6th Annual Oncology Care Summit to assess nurses' familiarity with and desire to understand novel oncology treatment options, including chimeric antigen receptor (CAR) T-cell therapies, cyclin-dependent kinase (CDK)4/6 inhibitors, immune checkpoint inhibitors, poly-ADP ribose polymerase (PARP) inhibitors, and antibody-drug conjugates. CAR T-cell therapy has been sho...

Continue reading

FDA Oncology Approvals in 2022: Timeline of Novel Treatment Options

The past year has been filled with new and exciting improvements and novel treatment options in the field of oncology and hematology. The FDA has granted approval and accelerated approval to many new drugs and drug combinations, including the very first approval for patients with HER2-mutant non–small cell lung cancer, trastuzumab deruxtecan. This is a great time to reflect on the current treatment landscape and ponder what 2023 could have in store for future approvals and emerging treatment opt...

Continue reading